Related Experiment Videos
Current management of polymyositis and dermatomyositis
1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, School of Medicine, Pennsylvania.
Drugs
|March 1, 1989
Summary
This review covers polymyositis and dermatomyositis, detailing pharmacological treatments like corticosteroids and immunosuppressants. It offers management strategies, including drug tapering and an algorithmic approach for refractory cases.
Area of Science:
- Rheumatology
- Immunology
- Neurology
Background:
- Polymyositis and dermatomyositis are idiopathic inflammatory myopathies.
- These conditions present with muscle weakness and other systemic complaints.
- Effective management requires a comprehensive therapeutic strategy.
Purpose of the Study:
- To review the clinical features of polymyositis and dermatomyositis.
- To emphasize current and emerging treatment strategies.
- To provide a practical management approach for refractory disease and associated symptoms.
Main Methods:
- Review of existing literature on polymyositis and dermatomyositis treatment.
- Discussion of pharmacological interventions, including corticosteroids and immunosuppressive agents.
- Outline of strategies for drug initiation, tapering, and management of refractory cases.
Main Results:
- Corticosteroids and immunosuppressive agents are primary treatments.
- Algorithmic approaches aid in managing myositis.
- Strategies for refractory disease and non-muscular complaints are essential.
Conclusions:
- Optimal management of polymyositis and dermatomyositis involves tailored pharmacological therapy.
- Addressing refractory disease and extraskeletal manifestations improves patient outcomes.
- A structured, algorithmic approach facilitates effective treatment and monitoring.